

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Brilliant Violet 510(TM) anti-human CD3

RRID:AB_2561943

Type: Antibody

Proper Citation

BioLegend Cat# 317332, RRID:AB_2561943

Antibody Information

URL: http://antibodyregistry.org/AB_2561943

Proper Citation: BioLegend Cat# 317332, RRID:AB_2561943

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2561943

Vendor: BioLegend

Catalog Number: 317332

Alternative Catalog Numbers: 317331

Record Creation Time: 20250820T044158+0000

Record Last Update: 20250820T194121+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yan X, et al. (2026) KRASG12/13 mutation modulates CRC outcomes via disrupting positive feedback between macrophage and CD4+ T cell. *iScience*, 29(1), 114402.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. *Cell stem cell*, 33(6), 982.

Kasahara S, et al. (2026) Safety and immunogenicity of an adjuvant-free peptide vaccine targeting IL-17A: Phase 1 randomized controlled trial. *iScience*, 29(8), 116817.

Lam N, et al. (2025) Asynchronous aging and turnover of human circulating and tissue-resident memory T cells across sites. *Immunity*, 58(9), 2271.

Spangler A, et al. (2025) Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later. *Immunity*, 58(3), 728.

Dacon C, et al. (2025) Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein. *Science (New York, N.Y.)*, 387(6729), eadr0510.

Mantus GE, et al. (2025) Distinct binding modes drive the broad neutralization profile of two persistent influenza hemagglutinin stem-specific antibody lineages. *Structure (London, England : 1993)*, 33(5), 869.

Joyce MG, et al. (2025) Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350. *Immunity*, 58(2), 295.

Arora JK, et al. (2024) Single-cell RNA sequencing reveals the expansion of circulating tissue-homing B cell subsets in secondary acute dengue viral infection. *Heliyon*, 10(10), e30314.

Hofman T, et al. (2024) IFN γ mediates the resistance of tumor cells to distinct NK cell subsets. *Journal for immunotherapy of cancer*, 12(7).

Schweiger P, et al. (2024) Functional Heterogeneity of Umbilical Cord Blood Monocyte-Derived Dendritic Cells. *Journal of immunology* (Baltimore, Md. : 1950), 213(2), 115.

Lederhofer J, et al. (2024) Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. *Immunity*, 57(3), 574.

Minute L, et al. (2024) Heat-killed *Mycobacterium tuberculosis* induces trained immunity in vitro and in vivo administered systemically or intranasally. *iScience*, 27(2), 108869.

Wang LT, et al. (2024) Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5. *Cell*, 187(18), 4981.

Dyikanov D, et al. (2024) Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer cell*, 42(5), 759.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Touizer E, et al. (2023) Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. *iScience*, 26(1), 105862.

de Cevins C, et al. (2023) Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response. *Cell reports. Medicine*, 4(12), 101333.

Dacon C, et al. (2023) Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. *Cell host & microbe*, 31(1), 97.